McNicoll Lewis & Vlak Downgrades Zalicus (ZLCS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
Zalicus (ZLCS) Announces Statistically Significant Results from Synavive in RA, But Misses Secondary Endpoint
September 10, 2012 8:02 AM EDTZalicus Inc. (NASDAQ: ZLCS) announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive® in rheumatoid arthritis (RA).
The Phase 2b trial demonstrated that patients treated with Synavive achieved a statistically significant improvement in signs and... More
